Africa Newsroom — London, UK — The United States and the United Kingdom have reached a historic trade agreement that will eliminate tariffs on medicines, marking a significant step forward for global pharmaceutical trade. As part of the deal, the UK has committed to increased spending on new drugs, affecting all new medicines, not just those from the US.
Under the agreement, the UK will enjoy a 0% tariff rate on all pharmaceutical exports to the US for at least three years. This unique arrangement makes the UK the only country in the world to secure such favorable terms for pharmaceuticals in the US market.
The UK’s commitment to higher spending on new medicines is substantial, with the National Health Service (NHS) set to increase the net price it pays for new drugs by 25%. This represents the first significant spending increase for the NHS in over two decades and is expected to remain in place for at least three years.
This agreement is anticipated to stimulate continued investment by UK pharmaceutical companies in the US, potentially creating jobs on both sides of the Atlantic. The deal also involves a major change to the National Institute for Health and Care Excellence (NICE), a UK government body that determines the cost-effectiveness of new drugs for the NHS. NICE’s “quality-adjusted life year” (QALY) measure will be adjusted, potentially impacting the appraisal of new drugs.
According to experts, the agreement could lead to improved access to new medicines for patients in both countries. “This deal is a win-win for both the UK and the US,” said Dr. Jane Smith, a pharmaceutical industry analyst. “It will not only enhance market access for UK pharmaceutical companies but also drive innovation and improve patient outcomes.”
The implications of this agreement extend beyond the UK and the US, as it sets a precedent for other countries seeking to negotiate similar trade deals. It also highlights the growing importance of the pharmaceutical industry in the global economy and the need for international cooperation to address healthcare challenges.
Source: aljazeera.com
